Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The CRuSADE PH Study
NCT03726398Phase 3Withdrawn
- Start
- Sep 2018
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of macitentan in pulmonary hypertension (PH). Primary endpoint: Exercise Pulmonary Vascular Resistance at 6 months. Planned start Sep 2018; status: withdrawn.
02
Drugs
macitentan
03
Conditions
pulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT03726398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03726398.